mebhydroline has been researched along with Diabetes Mellitus, Type 2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; He, A; Li, H; Li, S; Lu, J; Lv, J; Qian, M; Shen, X; Wang, J; Wang, S; Zhao, T | 1 |
1 other study(ies) available for mebhydroline and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist.
Topics: Animals; Blood Glucose; Carbolines; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gluconeogenesis; Glucose; HEK293 Cells; Homeostasis; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Docking Simulation; Protein Interaction Domains and Motifs; Receptors, Cytoplasmic and Nuclear; Streptozocin | 2021 |